-
Je něco špatně v tomto záznamu ?
Střednědobé výsledky perkutánní léčby závažné sekundární mitrální insuficience pomocí systému MitraClip u nemocných se srdečním selháním
[Mid-term results of percutaneous treatment of severe mitral regurgitation with MitraClip in patients with heart failure]
Michaela Červinková, Jiří Hlaváček, Petr Vojtíšek, Martin Kvašňák, Pavel Červinka
Jazyk čeština Země Česko
- Klíčová slova
- MitraClip,
- MeSH
- koronární angioplastika metody MeSH
- lidé MeSH
- mitrální insuficience * terapie MeSH
- retrospektivní studie MeSH
- Check Tag
- lidé MeSH
Cíl: Autoři prezentují střednědobé výsledky perkutánní léčby mitrální insuficience pomocí systému MitraClip (Abbott Vascular, Santa Clara, CA, USA).
Objective: The authors present mid-term results of percutaneous treatment of mitral insufficiency using the MitraClip system (Abbott Vascular, Santa Clara, CA, USA). Methodology: The group consists of 59 patients with severe mitral regurgitation and heart failure in whom cardiac surgery was contraindicated (EuroScore II 8.1 %). The average age was 71 years (± 13), most of which were male (56 %). The left ventricular ejection fraction was 32.5 ± 6.5 %, the majority (79 %) of patients were NYHA class 3/4. Results: The procedure was technically successful in 100 % of cases. Immediately after the procedure, the mean mitral regurgitation was reduced from 3.7 to 1.3 degrees/4 (p < 0.0001). The patients underwent 6 (N = 55), 12 (N = 47), and 24 (N = 28) months of clinical follow-up with transthoracic echocardiography (TTE) with overall mortality of 11 %, 12.7 %, and 32 % and cardiovascular mortality of 3.6 %, 4.3 %, and 10.7 %, respectively. According to TTE, the mean mitral regurgitation grade during follow-up was 1.75, 2.1, and 2.3 degrees out of 4 (for all p < 0.001 values, compared with an average mitral regurgitation of 3.7/4 degrees before the procedure). The average NYHA class score during follow-up was 1.85, 1.9, and 1.9/4 (for all p < 0.001 values), compared with the NYHA class before the procedure. Conclusions: The authors confirmed the efficacy and safety of percutaneous treatment using MitraClip in a carefully selected group of patients with severe secondary mitral regurgitation and heart failure with left ventricular systolic dysfunction.
KAPIM Krajská zdravotní a s Masarykova nemocnice v Ústí nad Labem o z Ústí nad Labem
Klinika kardiologie Krajská zdravotní a s Masarykova nemocnice v Ústí nad Labem o z Ústí nad Labem
Mid-term results of percutaneous treatment of severe mitral regurgitation with MitraClip in patients with heart failure
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21022775
- 003
- CZ-PrNML
- 005
- 20220106075649.0
- 007
- ta
- 008
- 210913s2021 xr ad f 000 0|cze||
- 009
- AR
- 024 7_
- $a 10.36290/kar.2021.029 $2 doi
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a cze $b eng
- 044 __
- $a xr
- 100 1_
- $a Červinková, Michaela $7 xx0148506 $u Klinika kardiologie, Krajská zdravotní, a. s., Masarykova nemocnice v Ústí nad Labem, o. z., Ústí nad Labem
- 245 10
- $a Střednědobé výsledky perkutánní léčby závažné sekundární mitrální insuficience pomocí systému MitraClip u nemocných se srdečním selháním / $c Michaela Červinková, Jiří Hlaváček, Petr Vojtíšek, Martin Kvašňák, Pavel Červinka
- 246 31
- $a Mid-term results of percutaneous treatment of severe mitral regurgitation with MitraClip in patients with heart failure
- 520 3_
- $a Cíl: Autoři prezentují střednědobé výsledky perkutánní léčby mitrální insuficience pomocí systému MitraClip (Abbott Vascular, Santa Clara, CA, USA).
- 520 9_
- $a Objective: The authors present mid-term results of percutaneous treatment of mitral insufficiency using the MitraClip system (Abbott Vascular, Santa Clara, CA, USA). Methodology: The group consists of 59 patients with severe mitral regurgitation and heart failure in whom cardiac surgery was contraindicated (EuroScore II 8.1 %). The average age was 71 years (± 13), most of which were male (56 %). The left ventricular ejection fraction was 32.5 ± 6.5 %, the majority (79 %) of patients were NYHA class 3/4. Results: The procedure was technically successful in 100 % of cases. Immediately after the procedure, the mean mitral regurgitation was reduced from 3.7 to 1.3 degrees/4 (p < 0.0001). The patients underwent 6 (N = 55), 12 (N = 47), and 24 (N = 28) months of clinical follow-up with transthoracic echocardiography (TTE) with overall mortality of 11 %, 12.7 %, and 32 % and cardiovascular mortality of 3.6 %, 4.3 %, and 10.7 %, respectively. According to TTE, the mean mitral regurgitation grade during follow-up was 1.75, 2.1, and 2.3 degrees out of 4 (for all p < 0.001 values, compared with an average mitral regurgitation of 3.7/4 degrees before the procedure). The average NYHA class score during follow-up was 1.85, 1.9, and 1.9/4 (for all p < 0.001 values), compared with the NYHA class before the procedure. Conclusions: The authors confirmed the efficacy and safety of percutaneous treatment using MitraClip in a carefully selected group of patients with severe secondary mitral regurgitation and heart failure with left ventricular systolic dysfunction.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a mitrální insuficience $x terapie $7 D008944
- 650 _2
- $a koronární angioplastika $x metody $7 D062645
- 650 _2
- $a retrospektivní studie $7 D012189
- 653 00
- $a MitraClip
- 700 1_
- $a Hlaváček, Jiří $7 xx0266498 $u Klinika kardiologie, Krajská zdravotní, a. s., Masarykova nemocnice v Ústí nad Labem, o. z., Ústí nad Labem
- 700 1_
- $a Vojtíšek, Petr $7 xx0248620 $u KAPIM, Krajská zdravotní, a. s., Masarykova nemocnice v Ústí nad Labem, o. z., Ústí nad Labem
- 700 1_
- $a Kvašňák, Martin $7 xx0241865 $u Klinika kardiologie, Krajská zdravotní, a. s., Masarykova nemocnice v Ústí nad Labem, o. z., Ústí nad Labem
- 700 1_
- $a Červinka, Pavel, $d 1964- $7 xx0139185 $u Klinika kardiologie, Krajská zdravotní, a. s., Masarykova nemocnice v Ústí nad Labem, o. z., Ústí nad Labem $u Univerzita Jana Evangelisty Purkyně v Ústí nad Labem
- 773 0_
- $t Intervenční a akutní kardiologie $x 1213-807X $g Roč. 20, č. 2 (2021), s. 102-105 $w MED00012578
- 856 41
- $u https://www.iakardiologie.cz/artkey/kar-202102-0009_strednedobe_vysledky_perkutanni_lecby_zavazne_sekundarni_mitralni_insuficience_pomoci_systemu_mitraclip_u_nemoc.php $y plný text volně přístupný
- 910 __
- $a ABA008 $b B 2286 $c 400 a $y p $z 0
- 990 __
- $a 20210913 $b ABA008
- 991 __
- $a 20220106075646 $b ABA008
- 999 __
- $a ok $b bmc $g 1700493 $s 1143259
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 20 $c 2 $d 102-105 $e 20210709 $i 1213-807X $m Intervenční a akutní kardiologie $x MED00012578
- LZP __
- $c NLK109 $d 20211026 $b NLK124 $a Actavia-MED00012578-20210913
